Skip to main content

Advertisement

Table 4 Comparison of adverse events of MMF and CYC therapy

From: Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial

Parameter CYC (N = 21) MMF (N = 21) P value Odds ratio 95% Confidence interval
Alopecia 16 (76.2%) 0 (0.00%) <.001 n/a n/a
Nausea/Vomiting 16 (76.2%) 0 (0.0%) <.001 n/a n/a
Headache 8 (38.09%) 4 (19.04%) 0.778 0.423 0.084–3.456
Backache 6 (28.57%) 4 (19.04%) 0.887 0.632 0.094–4.230
Urinary tract infection 4 (19.04%) 2 (9.52%) 0.796 0.473 0.083–3.492
Herpes Zoster 3 (14.3%) 3 (14.3%) 0.337 1.000 0.178–5.632
Chest Infection 3 (14.3%) 2 (9.5%) 0.328 0.632 0.094–4.230